* Oscar Health Inc is expected to show a rise in quarterly revenue when it reports results on November 7 for the period ending September 30 2024

* The New York City-based company is expected to report a 62.4% increase in revenue to $2.339 billion from $1.44 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Oscar Health Inc is for a loss of 17 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Oscar Health Inc is 27.50​, above​ its last closing price of $18.34. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jan. 1 0001 0.17 0.16 0.20 Beat 23.7

Mar. 31 0001 0.27 0.27 0.62 Beat 127.9

Dec. 31 2023 -0.73 -0.72 -0.66 Beat 8.7​

Sep. 30 2023 -0.47 -0.47 -0.29 Beat 38.6

​​Jun. -0.22 -0.23 -0.07 Beat 69.6

30 2023

Mar. 31 2023 -0.04 -0.05 -0.18 Missed -254.7

​

Dec. 31 2022 -1.09 -1.16 -1.05 Beat 9.5

Sep. 30 2022 -0.72 -0.73 -0.91 Missed -24.6

This summary was machine generated November 6 at 14:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)